Any feedback?
Literature summary for 3.2.1.76 extracted from
- AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys (2009), J. Biotechnol., 144, 135-141.
Application
| Application | Comment | Organism |
|---|---|---|
| drug development | mutant AGT-181 might be useful as a therapeutic approach to treatment of the brain in Hurlers syndrome | Homo sapiens |
Protein Variants
| Protein Variants | Comment | Organism |
|---|---|---|
| additional information | construction of a protein mutant AGT-181, that is a genetically engineered fusion protein of human iduronidase and a chimeric monoclonal antibody against the human insulin receptor. The mutant AG-181 is administered to Maccaca mulatta, chronic AGT-181 dosing does not result in toxicity at any dose, and causes no changes in organ histology, no change in plasma or cerebrospinal fluid glucose, and no significant immune response. AGT-181 is rapidly removed from plasma, but shows iduronidase enzyme activity | Homo sapiens |
Localization
| Localization | Comment | Organism | GeneOntology No. | Textmining |
|---|---|---|---|---|
| lysosome | - |
Homo sapiens | 5764 | - |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| iduronidase | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
